Ultragenyx agrees to sell PRV for $203 million
The sale of the FAYUVI voucher follows a previous transaction and provides non-dilutive funding to support pipeline development and profitability goals.
Latest Ultragenyx News & Updates
See the latest news and media coverage for Ultragenyx. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharmaceutical company developing and commercializing rare disease therapies
ultragenyx.com- Headquarters
- Novato, United States
- Founded year
- 2010
- Company type
- Public company
- Number of employees
- 1,500–5,000
- Industry
- Pharmaceuticals
Last updated
Latest news about Ultragenyx
In short: Ultragenyx won two gene-therapy approvals, sold a $203M PRV, and posted record revenue despite an Angelman failure.
Company announcements
Ultragenyx sells rare pediatric disease priority review voucher for $210 million
The sale of the voucher provides significant non-dilutive capital to advance therapies for rare diseases and supports the company's path to profitability, pending standard closing conditions.
Ultragenyx receives FDA approval for FAYUVI gene therapy
It is the first treatment for Sanfilippo Syndrome Type A, marking Ultragenyx's second gene therapy approval and earning a Priority Review Voucher.
Ultragenyx announces failed Phase 3 results for Angelman syndrome therapy
The investigational antisense oligonucleotide missed cognitive and responder endpoints while maintaining its established safety profile. The company will reassess the program and implement cost reductions to support commercial operations.
Media coverage
Analysts Watch RevMed Launch and Merck Data for Q3 Earnings
Investors monitor Johnson & Johnson earnings start, RevMed's Rasonque sales, Jazz Pharmaceuticals expansion, Ultragenyx launches, and Merck clinical data.
Ultragenyx Monetizes FDA Priority Review Voucher Asset
Detailed price information for Ultragenyx Pharmaceu (RARE-Q) from The Globe and Mail including charting and trades.
EU Medicines Regulator Validates Ultragenyx's Investigational Sanfilippo Syndrome Treatment
Ultragenyx shares crater after Angelman syndrome drug fails late-stage trial RE Sep. 03 Ultragenyx Rare Neurogenetic Disorder Phase 3 Study Misses Endpoints; Shares Down Pre-Bell...
Ultragenyx announces submission of Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the first experimental gene therapy for MPS IIIA (Sanfilippo...
Ultragenyx announced that the European Medicines Agency has accepted the company's Marketing Authorization Application for its experimental gene therapy Rebisufligene Etisparvovec for the treatment...
Never miss news about Ultragenyx
Track Ultragenyx and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Ultragenyx competitors & trending companies
Browse news for competitors to Ultragenyx and other trending companies.
Sobi
Jazz
Alnylam
Sarepta
Taysha
Avidity Biosciences
Hansa Biopharma
Wave Life Sciences
Intellia
BrandCrowd
Itancia
Paul, Weiss
Prime Medicine
AN2 Therapeutics
STRABAG
Clarke Energy
Altrad Babcock
Laing O’Rourke
Kier
T.EN
Bilfinger
Anesco
Mott MacDonald
Balfour Beatty
Heerema
Maire
TR
HOCHTIEF
SPIE
Eiffage
Kent
Petrofac
Costain
RSK Renewables
Flex
LOGO.com